Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites

Table 4

Incidence of treatment-emergent adverse events (TEAEs).

Parameter	(%)
At least one TEAE	6 (100)
Related TEAE	3 (50.0)
Serious TEAE	4 (66.7)
Serious-related TEAE	0
TEAE leading to drug withdrawal	3 (50.0)
Grade 3-4 TEAE	4 (66.7)
Fatal TEAE	0
Individual TEAEs
Diarrhea	3 (50.0)
Vomiting	2 (33.3)
Hypokalemia	2 (33.3)
Headache	3 (50.0)